ArticleCancers2022
Testicular Neoplasms: Primary Tumour Size Is Closely Interrelated with Histology, Clinical Staging, and Tumour Marker Expression Rates-A Comprehensive Statistical Analysis.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 21 citations in OpenAlex.
- Sizing up Testicular Masses: Clinical Implications of Lesion Size and Contralateral Biopsy.Cancers · 2026Article
- Multiparametric Ultrasound for Characterisation of Testicular Lesions: Beyond Orchiectomy.Diagnostics (Basel, Switzerland) · 2026Review
- Circulating MicroRNAs in Testicular Germ Cell Tumors: Biomarkers for Diagnosis, Surveillance, and Treatment Stratification.Journal of personalized medicine · 2026Review
- Machine learning of multiparametric MRI radiomics preoperatively distinguishes testicular seminoma from non-seminoma: a multicenter study.Abdominal radiology (New York) · 2026Article
- Diagnostic performance of the microRNA-371a assay in small testicular masses: a real-world cohort study.BJU international · 2026Article
- Pathological Tumour Volume Percentage as a Quantitative Biomarker of Biological Aggressiveness in High-Risk Prostate Cancer.Cancers · 2026Article
- Testicular mass frozen section examination: Pathological insights and diagnostic accuracy.Histopathology · 2026Article
- Independent factors associated with advanced testicular germ cell tumors: the roles of smoking, lymphovascular invasion, and tumor size.BMC cancer · 2026Article
- Giant testicular germ-cell tumours-An analysis of relative incidence and clinical features based on a clinical case series and a survey of the literature.BJUI compass · 2026Article
- Isolated testicular metastasis from prostate cancer following three years of hormone therapy and radiotherapy.Urology case reports · 2025Article
- Potential next generation markers of testicular germ cell tumors: miRNA-371a-3p.International urology and nephrology · 2025Review
- Commentary: Management of non-palpable subcentimeter testicular incidentalomas.Frontiers in oncology · 2025Article
- Perioperative Serum MicroRNA 371a-3p and 372-3p Levels in Patients with Clinically Localized Testicular Masses.European urology open science · 2024Article
- Myoid gonadal stromal tumor of the testis-the novel subtype of testicular gonadal stromal tumors: a case report and review of the literature.Journal of medical case reports · 2024Review
- Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Diagnosis and management of indeterminate testicular lesions.Nature reviews. Urology · 2024Review
- Review
- Testicular neoplasms: the interrelationships of serum levels of microRNA-371a-3p (M371) and classical tumor markers with histology, clinical staging, and age-a statistical analysis.Journal of cancer research and clinical oncology · 2023Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
The role of primary tumour size (TS) in the clinical course of testicular tumours is incompletely understood. We retrospectively evaluated 641 consecutive patients with testicular neoplasms with regard to TS, histology, clinical stage (CS), serum tumour marker (STM) expression and patient age using descriptive statistical methods. TS ≤ 10 mm was encountered in 13.6% of cases. Median TS of 10 mm, 30 mm, 35 mm, and 53 mm were found in benign tumours, seminomas, nonseminomas, and other malignant tumours, respectively. In cases with TS ≤ 10 mm, 50.6% had benign tumours. Upon receiver operating characteristics analysis, TS of > 16 mm revealed 81.5% sensitivity and 81.0% specificity for detecting malignancy. In subcentimeter germ cell tumours (GCTs), 97.7% of cases had CS1, and CS1 frequency dropped with increasing TS. Expression rates of all STMs significantly increased with TS. MicroRNA-371a-3p (M371) serum levels had higher expression rates than classical STMs, with a rate of 44.1% in subcentimeter GCTs. In all, TS is a biologically relevant factor owing to its significant associations with CS, STM expression rates and histology. Importantly, 50% of subcentimeter testicular neoplasms are of benign nature, and M371 outperforms the classical markers even in subcentimeter tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.